IPILIMUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT IN EXTENSIVE DISEASE-SMALL CELL LUNG CANCER (ED-SCLC): RESULTS FROM A PHASE 2 TRIAL

被引：0
|
作者：
Reck, Martin [1 ]
Bondarenko, Igor [2 ]
Luft, Alexander [3 ]
Serwatowski, Piotr
Barlesi, Fabrice [4 ]
Chacko, Raju [5 ]
Sebastian, Martin [6 ]
Siegel, Jonathan [7 ]
Cuillerot, Jean-Marie [7 ]
Lynch, Thomas [8 ,9 ]
机构：
[1] Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany
[2] City Clin Hosp, Kiev, Ukraine
[3] Leningrad Reg Clin Hosp, St Petersburg, Russia
[4] Univ Aix Marseille 2, Assistance Publ Hop Marseille, Marseille, France
[5] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
[6] Johannes Gutenberg Univ Med Ctr, Dept Hematol Oncol & Pneumol, Mainz, Germany
[7] Bristol Myers Squibb Co, New York, NY 10154 USA
[8] Yale Canc Ctr, Dept Oncol, New Haven, CT USA
[9] Smilow Canc Hosp, New Haven, CT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S310 / S311
页数：2
相关论文
共 50 条
  • [1] Phase II study of topotecan (T) and paclitaxel (P) as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED-SCLC)
    Hainsworth, J
    Palmer, M
    Granick, J
    Boston, B
    Bonomi, P
    Althouse, D
    Dharan, B
    Poulin, R
    Wissel, P
    LUNG CANCER, 2005, 49 : S320 - S320
  • [2] Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)
    Reck, M.
    Horn, L.
    Novello, S.
    Barlesi, F.
    Albert, I.
    Juhasz, E.
    Chung, J.
    Fritsch, A.
    Drews, U.
    Rutstein, M.
    Wagner, A.
    Govindan, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
    Reck, M.
    Bondarenko, I.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R.
    Sebastian, M.
    Lu, H.
    Cuillerot, J. -M.
    Lynch, T. J.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 75 - 83
  • [4] A phase II trial in patients with extensive disease small-cell lung cancer (ED-SCLC) with irinotecan, carboplatin and etoposide regimen as a front line treatment
    Syrigos, Konstantinos N.
    Charpidou, Andriani G.
    Pantazopoulos, Kosmas N.
    Dilana, Kalliopi
    Rigopoulou, Anna
    Georgatou, Niki
    Roussos, Charalampos
    ANNALS OF ONCOLOGY, 2006, 17 : 232 - 232
  • [5] IPILIMUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER: ANALYSIS BY BASELINE HISTOLOGY IN A PHASE 2 TRIAL
    Lynch, Thomas
    Bondarenko, Igor
    Luft, Alexander
    Serwatowski, Piotr
    Barlesi, Fabrice
    Chacko, Raju
    Sebastian, Martin
    Siegel, Jonathan
    Cuillerot, Jean-Marie
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S660 - S661
  • [6] Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial
    Ettinger, D. S.
    Jotte, R.
    Lorigan, P.
    Gupta, V.
    Garbo, L.
    Spigel, D.
    Dudek, A. Z.
    Salgia, R.
    McNally, R.
    Renschler, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 541 - 541
  • [7] Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: updated results of a phase 2 trial
    Ettinger, David S.
    Jotte, Robert M.
    Paul, Lorigan
    Gupta, Vicram
    Garbo, Lawrence
    Alemany, Carlos
    Spigel, David R.
    Dudek, Arkadiusz Z.
    Salgia, Ravi
    McNally, Richard
    Renschler, Markus
    Oliver, Jennifer W.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S398 - S399
  • [8] Radiochemotherapy in Extensive Disease Small Cell Lung Cancer ED-SCLC
    Jeremic, Branislav
    Casas, Francesc
    Wang, Luhua
    Perin, Branislav
    CONTROVERSIES IN TREATMENT OF LUNG CANCER, 2010, 42 : 180 - 186
  • [9] A NOVEL PHASE II TRIAL OF IPILIMUMAB, CARBOPLATIN AND ETOPOSIDE (ICE) FOR THE FIRST LINE TREATMENT OF EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC)
    Ottensmeier, C.
    Galea, I.
    Cross, N.
    Maishman, T.
    Hamid, D.
    Cave, J.
    Wheater, M.
    Geldart, T.
    Mulatero, C.
    Potter, V.
    Danson, S.
    Woll, P.
    Griffiths, R.
    Nolan, L.
    ANNALS OF ONCOLOGY, 2014, 25
  • [10] Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): Final results of a randomised phase III trial
    Heigener, D. F.
    Freitag, L.
    Eschbach, C.
    Huber, R. M.
    Fink, T.
    Hummler, S.
    Banik, N.
    Wolf, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345